CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
47.69
-2.40 (-4.79%)
At close: Mar 18, 2026, 4:00 PM EDT
47.56
-0.13 (-0.27%)
After-hours: Mar 18, 2026, 7:59 PM EDT
CRISPR Therapeutics AG Employees
CRISPR Therapeutics AG had 393 employees as of December 31, 2024. The number of employees decreased by 14 or -3.44% compared to the previous year.
Employees
393
Change (1Y)
-14
Growth (1Y)
-3.44%
Revenue / Employee
$8,931
Profits / Employee
-$1,479,896
Market Cap
4.58B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 393 | -14 | -3.44% |
| Dec 31, 2023 | 407 | -51 | -11.14% |
| Dec 31, 2022 | 458 | -15 | -3.17% |
| Dec 31, 2021 | 473 | 63 | 15.37% |
| Dec 31, 2020 | 410 | 106 | 34.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 399 |
| Xenon Pharmaceuticals | 370 |
| Immunovant | 362 |
| Scholar Rock Holding | 289 |
| Apogee Therapeutics | 261 |
| Celcuity | 87 |
CRSP News
- 7 days ago - CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering - GlobeNewsWire
- 8 days ago - CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering - GlobeNewsWire
- 27 days ago - Crispr Therapeutics: Very High Risk But Even Higher Potential Reward - Seeking Alpha
- 4 weeks ago - CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript - Seeking Alpha
- 4 weeks ago - CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 - Seeking Alpha
- 4 weeks ago - CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
- 4 weeks ago - CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Crispr Therapeutics: Patience And Opportunity Through Volatility - Seeking Alpha